NEW YORK (GenomeWeb) – In the wake of receiving a CLIA waiver for its rapid, point-of-care PCR testing device, Roche executives this week provided an update on the platform's infectious disease test menu pipeline.
The platform, called the Roche cobas Liat, received CLIA waiver yesterday along with a 15-minute molecular assay for group A Streptococcus.
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
